MENU
+Compare
BMRN
Stock ticker: NASDAQ
AS OF
Aug 1 closing price
Price
$58.14
Change
+$0.29 (+0.50%)
Capitalization
11.15B

BMRN BioMarin Pharmaceutical Forecast, Technical & Fundamental Analysis

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases... Show more

Industry: #Biotechnology
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BMRN with price predictions
Aug 01, 2025

BMRN in upward trend: price rose above 50-day moving average on July 22, 2025

BMRN moved above its 50-day moving average on July 22, 2025 date and that indicates a change from a downward trend to an upward trend. In of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 01, 2025. You may want to consider a long position or call options on BMRN as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for BMRN crossed bullishly above the 50-day moving average on July 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 154 cases where BMRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BMRN moved out of overbought territory on July 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where BMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BMRN turned negative on July 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BMRN broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.925) is normal, around the industry mean (17.448). P/E Ratio (21.533) is within average values for comparable stocks, (58.797). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (2.618). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (3.862) is also within normal values, averaging (276.708).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BMRN is expected to report earnings to fall 26.37% to 83 cents per share on August 04

BioMarin Pharmaceutical BMRN Stock Earnings Reports
Q2'25
Est.
$0.83
Q1'25
Beat
by $0.43
Q4'24
Beat
by $0.37
Q3'24
Beat
by $0.38
Q2'24
Beat
by $0.61
The last earnings report on May 01 showed earnings per share of $1.13, beating the estimate of 69 cents. With 3.82M shares outstanding, the current market capitalization sits at 11.15B.
A.I. Advisor
published General Information

General Information

a developer of innovative pharmaceuticals for serious diseases & medical conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
770 Lindaro Street
Phone
+1 415 506-6700
Employees
3401
Web
https://www.biomarin.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FTSD90.540.11
+0.13%
Franklin Short Duration US Govt ETF
EURHKD8.97N/A
N/A
Euro - Hong Kong Dollar
CHFHKD9.64-0.01
-0.07%
Switzerland Franc - Hong Kong Dollar
AUDCHF0.52-0.00
-0.19%
Australian Dollar - Switzerland Franc
FOCT44.95-0.64
-1.40%
FT Vest US Equity Buffer ETF Oct

BMRN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with ITOS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+0.50%
ITOS - BMRN
49%
Loosely correlated
-0.49%
SRPT - BMRN
45%
Loosely correlated
-3.11%
IONS - BMRN
42%
Loosely correlated
+0.12%
AXON - BMRN
42%
Loosely correlated
-1.72%
IBO - BMRN
42%
Loosely correlated
+0.57%
More